Nyxoah S.A. has reported a strong start to its U.S. commercialization of the Genio system, following FDA approval in August 2025. The company generated $4.5 million in revenue during Q4 2025, driven by initial sales from 125 high-volume hypoglossal nerve stimulation accounts. With a growing sales force and a focus on reimbursement clarity from both Medicare and commercial payers, Nyxoah is well-positioned to expand its market presence.
The financial results indicate a significant year-over-year revenue increase, with full-year net revenue reaching €10 million, a 122% rise from 2024. Despite ongoing operating losses of €83.5 million, the company maintains a robust cash position of €48 million, supporting its aggressive U.S. market strategy. The anticipated growth in U.S. net revenue by 25% in 2026 reflects Nyxoah’s commitment to enhancing surgeon engagement and expanding its sales coverage.
For market professionals, the key takeaway is Nyxoah’s potential for sustained growth in the hypoglossal nerve stimulation market, bolstered by strong initial sales performance and a clear reimbursement framework that should facilitate further adoption of the Genio system.
Source: fool.com